

01
阿新冠病毒威胁未减
泰中定®成防护新选择
02
从临床数据看疗效:
泰中定®在多个维度超越Paxlovid

03
泰中定®:
实惠又有效的新馆治疗选择
参考来源:
-
Hongzhou Lu, George Zhang, John Mao, et al. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial. eClinicalMedicine. 2024;71:102582.
-
https://www.who.int/zh/news/item/10-11-2023-who-updates-guidelines-on-treatments-for-covid-19
-
http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a/files/460b0e7b19bd42f3bba00c1efb9b6811.pdf
本篇文章来源于微信公众号: 药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权